Results 141 to 150 of about 790,096 (261)

Pharmaceuticals’ Strategic Interactions: Three Essays in Corporate Finance [PDF]

, 2013
The aim of this dissertation is to examine critical issues that pharmaceutical industry currently facing through lenses of corporate finance theories.
Hyttinen, Lilia
core  

Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product

Ophthalmology and Therapy
Introduction ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders.
Neungseon Seo, Xiaoyan Guan, Tian Wang, Hyo S. Helen Chung, Mats Wikström, Rupa Padaki, Kevin Kalenian, Scott Kuhns, Kelli Matthies, Jill Crouse-Zeineddini, Helen Y. Wong, Michael Ng, Ian N. Foltz, Shawn Cao, Jennifer Liu   +14 more
doaj   +1 more source

Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study [PDF]

Debdulal Chakraborty,1 Tushar Kanti Sinha,1 Sourav Sinha,2 Rupak Kanti Biswas,2 Aniruddha Maiti,3 Krishnendu Nandi,2 Dinesh Rungta,1 Ranabir Bhattacharya1 1Vitreo-Retina Services, Disha Eye Hospitals, Kolkata, WB, India; 2Vitreo-retina Services ...
Nandi K, Chakraborty D, Sinha S, Biswas RK, Bhattacharya R, Maiti A, Sinha TK, Rungta D   +7 more
core  

Comparative physicochemical and structural characterisation studies establish high biosimilarity between BGL-ASP and reference insulin aspart

Scientific Reports
Biosimilar insulin analogues are increasing market access for diabetic patients globally. Scientific establishment of biosimilarity is cornerstone of this key change in the medical landscape.
Nikhil S. Ghade, Damodar K. Thappa, Jeseena Lona, Archana R. Krishnan, Sanjay M. Sonar   +4 more
doaj   +1 more source

Changes In The Prices Of Reference Biotechnology Products By The Penetration Of Biosimilars Into The Turkish Pharmaceutical Market [PDF]

Value in Health, 2015
Kockaya, G., Tuna, E.
openaire   +2 more sources

Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation? [PDF]

We study the relationship between regulatory regimes and pharmaceutical firms’ pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called “index pricing” for a sub-sample of off-patent ...
Holmås, Tor Helge, Brekke, Kurt R., Grasdal, Astrid L.   +2 more
core  

Assessing Functional Similarity of Biosimilar ABP 654 and Ustekinumab in Samples from Patients with Crohn’s Disease

Journal of Inflammation Research
Ian N Foltz,1 Kevin Gaida,2 Helen Y Wong,1 Michael Ng,1 Marijana Busch,1 Jennifer L Liu3 1Amgen Research, Department of Therapeutic Discovery, Amgen Inc., Burnaby, BC, V5A1V7, Canada; 2Research and Development, Amgen Inc., Thousand Oaks, CA, 91320, USA ...
Foltz IN, Gaida K, Wong HY, Ng M, Busch M, Liu JL   +5 more
doaj  

Which drugs will Medicare negotiate next? Predicting selected drugs for Initial Price Applicability Year 2029. [PDF]

J Manag Care Spec Pharm
Li KH, Cousin EM, Sullivan SD.
europepmc   +1 more source

Real-World Comparison of Biosimilar Ranibizumab (Ranieyes) and Innovator Ranibizumab (Lucentis/Accentrix) Across Multiple Retinal Vascular Diseases (The BRIO Study). [PDF]

Pharmaceuticals (Basel)
Chakraborty D, Sinha TK, Sinha S, Biswas RK, Das A, Maiti A, Bhattacharya R, Dan S, Rungta D, Das S.   +9 more
europepmc   +1 more source

The Impact of Biosimilar Launch on Molecule Price and Pharmaceutical Expense: The Case of the Insulin Glargine in Italy [PDF]

Value in Health, 2017
A Tettamanti, L Cioni, C Tucci
openaire   +1 more source